Penumbra, Inc. (NYSE:PEN) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Jeremy, and I will be your conference operator today. At this time, I would like to welcome everybody to Penumbra's Third Quarter 2024 Conference Call.
Penumbra Inc (PEN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 265,000 | $47,692,050 | -48% | 1.43% |
| 2. | Braidwell LP Alex Karnal | 212,594 | $38,260,542 | -29% | 1.2% |
| 3. | Partner Fund Management Christopher Medlock James | 185,111 | $33,314,427 | +19% | 1.64% |
| 4. | AQR Capital Management Cliff Asness | 178,413 | $31,282,936 | +440% | 0.04% |
| 5. | GLG Partners Noam Gottesman | 124,528 | $22,411,304 | +37% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $156.40 | 700 | Director | 3,850 | 2018-05-25 | Filing | |
| $25.50 | 1,538 | Officer | 2,538 | 2016-05-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.53 | 1,000 | Officer, Director | 867,582 | 2024-10-21 | Filing | |
| $205.61 | 3,275 | Officer, Director | 868,582 | 2024-10-21 | Filing | |
| $204.72 | 5,225 | Officer, Director | 871,857 | 2024-10-21 | Filing | |
| $203.82 | 3,200 | Officer, Director | 877,082 | 2024-10-21 | Filing | |
| $202.86 | 2,300 | Officer, Director | 880,282 | 2024-10-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,789,454 | $1,456,279,273 | 0.11% | |
| 2. | 4,000,365 | $1,006,251,814 | 0.02% | |
| 3. | 3,658,103 | $920,159,229 | 0.02% | |
| 4. | 2,677,789 | $673,587,473 | 0.16% | |
| 5. | 1,101,107 | $276,972,455 | 0.01% |
News See All
Penumbra, Inc. (NYSE:PEN) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everybody to Penumbra's Second Quarter 2024 Conference Call.
Penumbra, Inc. (NYSE:PEN) Q1 2024 Earnings Call Transcript
Penumbra, Inc. misses on earnings expectations. Reported EPS is $0.2793 EPS, expectations were $0.42.
Penumbra, Inc. (NYSE:PEN) Q4 2023 Earnings Call Transcript
Penumbra, Inc. beats earnings expectations. Reported EPS is $0.76, expectations were $0.71. Penumbra, Inc.
25 Most Valuable Medical Device Companies in the US
In this article, we will be taking a look at the 25 most valuable medical device companies in the US.
Is Penumbra (PEN) a Good Short Position?
Diamond Hill Capital, an investment management company, released its “Long-Short Fund” third-quarter 2023 investor letter. A copy of the same can be downloaded here.
Penumbra, Inc. (NYSE:PEN) Q3 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Adam and I will be your conference operator today. At this time, I would like to welcome everyone to Penumbra’s Third Quarter 2023 Conference Call.
Penumbra (PEN) Declined on Weak Second Quarter Earnings
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here.
Artisan Partners Small Cap Fund Trimmed Penumbra (PEN) Based on Valuation Discipline
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
5 Oversold Healthcare Stocks to Buy
Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization...